Proteinuria Therapeutics Market: Introduction
- Proteinuria is also known as albuminuria. It is a condition, in which the amount of protein present in urine is greater than normal. It is usually associated with some form of abnormality or disease, but can be occasionally seen in healthy individuals.
- Plasma contains several different proteins. One of the most important functions of kidneys is to conserve plasma protein so that it is not removed along with waste products when urine is produced. The two types of tissues that normally inhibit protein from passing into urine are tubules and glomeruli. Proteinuria often occurs when either the tubules or glomeruli in the kidneys are damaged.
- Scarring or/and inflammation of the glomeruli can allow increasing amounts of red blood cells (RBCs) and protein to leak into the urine. Damage to the tubules can prevent protein from being reabsorbed.
- Healthy people can have persistent or temporary proteinuria. Proteinuria can be associated with fever, stress, exposure to cold, and aspirin therapy. The most common reason for protein in the urine is kidney damage due to hypertension and diabetes.
- Medications such as angiotensin receptor blockers and angiotensin-converting enzyme inhibitors reduce proteinuria
Are you a Start-up willing to make it Big in the Business? Grab an Exclusive PDF Brochure of Proteinuria Therapeutics Market Report
Key Drivers of Global Proteinuria Therapeutics Market
- The global proteinuria therapeutics market is primarily driven by rise in prevalence and incidence of proteinuria across the world
- According to the National Health and Nutrition Examination Survey (NHANES III- 1988–1994), the prevalence of proteinuria in the U.S. was 9.7% in females and 6.1% in males. The prevalence of proteinuria in patients with diabetes was 28.8%, 16.0% in patients with hypertension, and 5.1% in those without cardiovascular disease, hypertension, diabetes, or elevated serum creatinine level.
Angiotensin-converting Enzyme (ACE) Inhibitors Segment Held Major Share of Global Market
- In terms of drug class, the global proteinuria therapeutics market can be divided into angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and others
- The angiotensin-converting enzyme (ACE) inhibitors segment is anticipated to dominate the global market during the forecast period
- Angiotensin-converting enzyme (ACE) inhibitors are highly preferred by clinicians and medicine manufacturers. This is anticipated to drive the segment during the forecast period.
Retail Pharmacies Segment to Offer Attractive Opportunities
- Based on distribution channel, the global proteinuria therapeutics market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies
- The retail pharmacies segment is expected to account for major share of the global proteinuria therapeutics market by 2027
- The segment’s dominance can be attributed to increase in sales of proteinuria therapeutics through retail channel
North America to Dominate Global Proteinuria Therapeutics Market
- In terms of region, the global proteinuria therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global market during the forecast period.
- Rise in prevalence of various risk factors related to proteinuria and increase in sales of off-label drugs for the treatment of the condition are anticipated to drive the segment during the forecast period.
Looking for Regional Analysis or Competitive Landscape in Forestry Machinery Market, Ask for a Customized Proteinuria Therapeutics Market Report
Key Players Operating in Global Market
Key players operating in the global proteinuria therapeutics market are:
- AbbVie, Inc.
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- Merck & Co. Inc.
- Novartis AG
- Pfizer, Inc.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
Global Proteinuria Therapeutics Market: Research Scope
Global Proteinuria Therapeutics Market, by Drug Class
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin Receptor Blockers (ARBs)
Global Proteinuria Therapeutics Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Proteinuria Therapeutics Market, by Region
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.